-
平臺編號：bio-69354
-
國際編號：CRL-5894?
-
細(xì)胞信息： NCI-H1781
-
規(guī)格：Frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準(zhǔn)）
NCI-H1781
年限：stage 3B
數(shù)量：大量
生長狀態(tài)：貼壁生長
器官來源：肺
是否是腫瘤細(xì)胞：1
物種來源：人
ATCC Number：CRL-5894?
運(yùn)輸方式：凍存運(yùn)輸
相關(guān)疾?。浩渌膊?br /> 規(guī)格：300 ul Designations: NCI-H1781 [H1781]
Depositors: ?AF Gazdar, JD Minna
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent
Organism: Homo sapiens
Morphology:
Source: Organ: lung
Tumor Stage: stage 3B
Disease: adenocarcinoma; bronchoalveolar carcinoma
Derived from metastatic site: pleural effusion
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions:The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 699-8056, FAX (214) 688-7233.
DNA Profile (STR):Amelogenin: X
CSF1PO: 10
D13S317: 14
D16S539: 8
D5S818: 10
D7S820: 9,10
THO1: 9
TPOX: 10,11
vWA: 14
Age: 66 years
Gender: female
Ethnicity: Caucasian
Comments:The line was established in November 1987.
The patient received prior chemotherapy and radiation therapy.
The patient was a smoker.
60 pack years.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended
Medium Renewal: Every 2 to 3 days
Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach.
Add fresh culture medium, aspirate and dispense into new culture flasks.
Preservation: Culture medium, 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 23570: . NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996..
數(shù)量：大量
生長狀態(tài)：貼壁生長
器官來源：肺
是否是腫瘤細(xì)胞：1
物種來源：人
ATCC Number：CRL-5894?
運(yùn)輸方式：凍存運(yùn)輸
相關(guān)疾?。浩渌膊?br /> 規(guī)格：300 ul Designations: NCI-H1781 [H1781]
Depositors: ?AF Gazdar, JD Minna
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent
Organism: Homo sapiens
Morphology:
Source: Organ: lung
Tumor Stage: stage 3B
Disease: adenocarcinoma; bronchoalveolar carcinoma
Derived from metastatic site: pleural effusion
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions:The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 699-8056, FAX (214) 688-7233.
DNA Profile (STR):Amelogenin: X
CSF1PO: 10
D13S317: 14
D16S539: 8
D5S818: 10
D7S820: 9,10
THO1: 9
TPOX: 10,11
vWA: 14
Age: 66 years
Gender: female
Ethnicity: Caucasian
Comments:The line was established in November 1987.
The patient received prior chemotherapy and radiation therapy.
The patient was a smoker.
60 pack years.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended
Medium Renewal: Every 2 to 3 days
Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach.
Add fresh culture medium, aspirate and dispense into new culture flasks.
Preservation: Culture medium, 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 23570: . NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996..
